Volastra Therapeutics, Inc., is developing novel therapies to treat and prevent the formation of metastatic disease.  Launched from the laboratory of Dr. Lewis Cantley, along with Drs. Olivier Elemento and Samuel Bakhoum, Volastra has identified the mechanisms by which CIN drives the formation and proliferation of metastases.  Following initial evidence that a patient’s CIN status is prognostic for metastasis and that CIN alters metastasis and overall survival in mouse models, the company is discovering mechanisms and pathways by which CIN modulates metastatic disease to develop novel therapeutics. 

Biotechnology

Volastra

Charles Hugh-Jones

Senior Vice President, Legal, Compliance, And Operations

Jacqueline Gonzalez

Scott Drutman

Rachel Zolot Schwartz

Joseph Avallone

Jianmin Mao

Michael Su

The Advisory Team at Volastra Therapeutics, Inc. comprises a group of esteemed experts who provide strategic guidance and insights to support the company's mission of developing novel therapies to treat and prevent metastatic disease. Leveraging their extensive backgrounds in cancer research, clinical practice, and therapeutic development, the advisors assist in refining research directions, evaluating clinical strategies, and fostering collaborations to accelerate the advancement of innovative treatments based on chromosomal instability (CIN) mechanisms.

Advisory Team

Leadership Team

Scientific Research Team

��

Advisory Team

About

Team members

Other teams at Volastra

Leadership Team

Scientific Research Team

��������

Advisory Team

About

Team members

Other teams at Volastra

Leadership Team

Scientific Research Team

��